PST3.1a is an orally active and brain-penetrant N-acetylglucosamine glycosyltransferase ( MGAT5 ) inhibitor with a human IC 50 of 2 µM. PST3.1a inhibits TGFβR and FAK signaling pathway activity. PST3.1a alters β1,6-GlcNAc N-glycans and microtubule/microfilament integrity, increases OLIG2 expression, and inhibits proliferation, migration, invasiveness, and clonogenic capacities of glioblastoma initiating cells. PST3.1a reduces invasive and proliferative capacity of glioblastoma initiating cells in orthotopic graft models, increases overall survival of orthotopic graft model mice. PST3.1a blunts MGAT5 overexpression, decreases renal fibrosis via collagen 1, collagen 4, and galectin 3 downregulation in a rat chronic kidney disease model. PST3.1a can be used for the research of glioblastoma multiforme and chronic kidney disease.
Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Renal Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Endocrinology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Galectin | Products > Signaling Pathways > Collagen | Products > Signaling Pathways > Glycosyltransferase | Products > Signaling Pathways > TGF-β Receptor | Products > Signaling Pathways > FAK
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye